---
title: "PDS Biotechnology updates corporate presentation highlighting Phase 3 VERSATILE-003, 39.3m mOS and upcoming catalysts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284050202.md"
description: "PDS Biotechnology has updated its corporate presentation, focusing on the progress of Phase 3 VERSATILE-003, which reports a 39.3-month median overall survival for PDS0101 combinations. The presentation highlights upcoming catalysts, including interim milestones for VERSATILE-003 and data publications for PDS01ADC programs in various cancers, expected in 2026-2027. The Phase 3 trial is FDA-aligned on the PFS interim endpoint, with 252 participants involved. The updated presentation was filed on April 24, 2026."
datetime: "2026-04-24T20:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284050202.md)
  - [en](https://longbridge.com/en/news/284050202.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284050202.md)
---

# PDS Biotechnology updates corporate presentation highlighting Phase 3 VERSATILE-003, 39.3m mOS and upcoming catalysts

**PDS Biotechnology updated its corporate presentation emphasizing Phase 3 VERSATILE-003 progress, reported 39.3-month median overall survival for PDS0101 combos and upcoming 2026 catalysts.**

**Key Highlights:**

-   Filed updated corporate presentation (Exhibit 99.1) on April 24, 2026 to summarize programs and data.
-   Reported PDS0101 + pembrolizumab mOS of 39.3 months and 77.4% disease control rate in 1L HPV16+ R/M HNSCC.
-   VERSATILE-003 Phase 3 underway (N=252), FDA-aligned on PFS interim endpoint enabling accelerated pathway.
-   Pipeline progress: PDS01ADC programs in colorectal, prostate and liver-associated cancers with several trials in progress.
-   Upcoming catalysts include VERSATILE-003 interim/readout milestones and PDS01ADC data publications in 2026–2027.

Original SEC Filing: PDS Biotechnology Corp \[ PDSB \] - 8-K - Apr. 24, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PDSB.US](https://longbridge.com/en/quote/PDSB.US.md)

## Related News & Research

- [ASP Releases Updated Investor Presentation, Notes Forward-Looking Statements](https://longbridge.com/en/news/287122849.md)
- [Athene posts fixed-income investor presentation for May 15, 2025 call](https://longbridge.com/en/news/286560329.md)
- [FS KKR Capital to post investor presentations on website after market close](https://longbridge.com/en/news/286815114.md)
- [Capital City Bank Group posts Q1 2026 investor presentation on website](https://longbridge.com/en/news/286599786.md)
- [Kairos publishes investor presentation, to present clinical program and partnering update at LD Micro Invitational](https://longbridge.com/en/news/286772069.md)